Targeted therapies driving innovation in the Gastric Cancer Drugs Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Gastric Cancer Drugs Market Over The Period 2026–2030?

The gastric cancer drugs market has experienced substantial growth in recent years. This market is projected to expand from $4.9 billion in 2025 to $5.39 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.9%. The historic period’s growth can be attributed to several factors, including the increasing prevalence of gastric cancer, insufficient awareness regarding early detection, a reliance on conventional chemotherapy, the rising adoption of hospital-based treatment, and the high cost associated with branded drugs.

The gastric cancer drugs market is projected to experience swift expansion in the coming years. This market is anticipated to reach $8.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. Factors contributing to this growth during the forecast period include progress in targeted treatments, rising acceptance of immunotherapy, the broadening scope of precision medicine, the creation of new oral and injectable drug forms, and increased financial support from both government and private entities for cancer research. Key trends anticipated over the forecast timeframe encompass individualized gastric cancer treatments, the emergence of targeted drug delivery mechanisms, a rise in the application of combination therapies, the extension of outpatient cancer care provisions, and an uptick in supportive care and symptom alleviation efforts.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

What Underlying Factors Are Accelerating The Growth Of The Gastric Cancer Drugs Market?

The increasing global aging population is projected to stimulate the expansion of the gastric cancer drug market. An aging population is characterized by a significant segment of a region’s inhabitants being older, typically 65 and above, a trend resulting from sustained increases in life expectancy and decreases in birth rates. Older patients frequently have reduced tolerance for standard cancer treatments, such as surgery or chemotherapy, thereby necessitating tailored treatment solutions, including drugs, to meet their specific needs and tolerances. For example, in July 2024, data from the UK Parliament’s House of Commons Library indicated that in 2022, 12.7 million individuals in the UK were aged 65 or older, constituting 19% of the total population. This figure is forecast to rise to 22.1 million by 2072, representing 27% of the population. Consequently, the gastric cancer drug market is anticipated to grow, driven by this expanding elderly demographic.

How Is The Gastric Cancer Drugs Market Divided Into Its Major Segments?

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

How Are Trends Transforming The Gastric Cancer Drugs Market Landscape?

Companies operating in the gastric cancer drugs market are actively developing innovative products, such as CLDN18.2-targeted treatments, aiming to enhance the effectiveness of therapies and offer more personalized options for patients. CLDN18.2-targeted treatment refers to therapies specifically designed to target claudin 18.2 (CLDN18.2), a protein primarily expressed in certain epithelial tissues, including the gastric epithelium. For instance, in October 2024, Astellas Pharma Inc., a Japan-based company, received approval from the Food and Drug Administration (FDA), a US-based federal agency tasked with protecting public health, for VYLOY (zolbetuximab). VYLOY (zolbetuximab) represents the inaugural CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer where tumors are CLDN18.2 positive. This treatment is administered in conjunction with fluoropyrimidine- and platinum-based chemotherapy regimens. It is indicated for adults diagnosed with locally advanced unresectable negative gastric or gastroesophageal junction cancer adenocarcinoma.

Who Are The Prominent Organizations Shaping The Gastric Cancer Drugs Market?

Major companies operating in the gastric cancer drugs market are F. Hoffmann-La Roche, Eli Lilly and Company, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Novartis Oncology, Arlak Biotech (India), CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene (China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc. (Japan), Daiichi Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Merck & Co. Inc., Pfizer Inc., Sandoz AG (Novartis), Eurofarma Laboratórios S.A., TUTEUR Argentina / Pierre Fabre Group, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Mylan Laboratories, Gilead Sciences, BMS

Read the full gastric cancer drugs market report here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Which Region Is Projected To Dominate The Gastric Cancer Drugs Market During The Forecast Period?

North America was the largest region in the gastric cancer drugs market in 2025. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gastric Cancer Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Drugs Market 2026, By The Business Research Company

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795